Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Jan 24;2007(1):CD004364.
doi: 10.1002/14651858.CD004364.pub2.

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia

T A Furukawa  1 , N Watanabe, R Churchill
Affiliations
Meta-Analysis

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia

T A Furukawa et al. Cochrane Database Syst Rev. .

Abstract

Background: Panic disorder can be treated with pharmacotherapy, psychotherapy or in combination, but the relative merits of combined therapy have not been well established.

Objectives: To review evidence concerning short- and long-term advantages and disadvantages of combined psychotherapy plus antidepressant treatment for panic disorder with or without agoraphobia, in comparison with either therapy alone.

Search strategy: The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 11/10/2005, together with a complementary search of the Cochrane Central Register of Controlled Trials and MEDLINE, using the keywords antidepressant and panic. A reference search, SciSearch and personal contact with experts were carried out.

Selection criteria: Two independent review authors identified randomised controlled trials comparing the combined therapy against either of the monotherapies among adult patients with panic disorder with or without agoraphobia.

Data collection and analysis: Two independent review authors extracted data using predefined data formats, including study quality indicators. The primary outcome was relative risk (RR) of "response" i.e. substantial overall improvement from baseline as defined by the original investigators. Secondary outcomes included standardised weighted mean differences in global severity, panic attack frequency, phobic avoidance, general anxiety, depression and social functioning and relative risks of overall dropouts and dropouts due to side effects.

Main results: We identified 23 randomised comparisons (representing 21 trials, 1709 patients), 21 of which involved behaviour or cognitive-behaviour therapies. In the acute phase treatment, the combined therapy was superior to antidepressant pharmacotherapy (RR 1.24, 95% confidence interval (CI) 1.02 to 1.52) or psychotherapy (RR 1.17, 95% CI 1.05 to 1.31). The combined therapy produced more dropouts due to side effects than psychotherapy (number needed to harm (NNH) around 26). After the acute phase treatment, as long as the drug was continued, the superiority of the combination over either monotherapy appeared to persist. After termination of the acute phase and continuation treatment, the combined therapy was more effective than pharmacotherapy alone (RR 1.61, 95% CI 1.23 to 2.11) and was as effective as psychotherapy (RR 0.96, 95% CI 0.79 to 1.16).

Authors' conclusions: Either combined therapy or psychotherapy alone may be chosen as first line treatment for panic disorder with or without agoraphobia, depending on patient preference.

PubMed Disclaimer

Conflict of interest statement

TAF has received research funding and fees for speaking from the following pharmaceutical companies: Asahi Kasei, Astellas, Dai‐Nippon, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Kyowa Hakko, Meiji, Organon, Pfizer, Tsumura and Yoshitomi.

Figures

Figure 1
Figure 1
Funnel plot for response at 2‐4 months on PT+AD vs AD alone
Figure 2
Figure 2
Analysis 1.1
Analysis 1.1
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 1.2
Analysis 1.2
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 1.3
Analysis 1.3
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 1.4
Analysis 1.4
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 1.5
Analysis 1.5
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 1.6
Analysis 1.6
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 1.7
Analysis 1.7
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 1.8
Analysis 1.8
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social malfunctioning at 2‐4 months.
Analysis 1.9
Analysis 1.9
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 1.10
Analysis 1.10
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 1.11
Analysis 1.11
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 1.12
Analysis 1.12
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 1.13
Analysis 1.13
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 1.14
Analysis 1.14
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 14 Response/remission immediately after treatment discontinuation.
Analysis 1.15
Analysis 1.15
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 15 Global/Avoidance/Panic immediately after treatment discontinuation.
Analysis 1.16
Analysis 1.16
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 1.17
Analysis 1.17
Comparison 1 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 2.1
Analysis 2.1
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 1 Response at 2‐4 months.
Analysis 2.2
Analysis 2.2
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 2 Remission at 2‐4 months.
Analysis 2.3
Analysis 2.3
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 3 Global severity at 2‐4 months.
Analysis 2.4
Analysis 2.4
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 2.5
Analysis 2.5
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 2.6
Analysis 2.6
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 2.7
Analysis 2.7
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 7 Depression at 2‐4 months.
Analysis 2.8
Analysis 2.8
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 8 Social malfunctioning at 2‐4 months.
Analysis 2.9
Analysis 2.9
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 2.10
Analysis 2.10
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 2.11
Analysis 2.11
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 11 Response/remission on continued treatment.
Analysis 2.12
Analysis 2.12
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 12 GlobalAvoidance/Panic on continued treatment.
Analysis 2.13
Analysis 2.13
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 2.14
Analysis 2.14
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 14 Response/remission 6‐24 months after treatment discontinuation.
Analysis 2.15
Analysis 2.15
Comparison 2 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone, Outcome 15 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 3.1
Analysis 3.1
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 1 Response at 2‐4 months.
Analysis 3.2
Analysis 3.2
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 3.3
Analysis 3.3
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 3.4
Analysis 3.4
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 3.5
Analysis 3.5
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 3.6
Analysis 3.6
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 3.7
Analysis 3.7
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 3.8
Analysis 3.8
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 8 Social malfunctioning at 2‐4 months.
Analysis 3.9
Analysis 3.9
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 3.10
Analysis 3.10
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 3.11
Analysis 3.11
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 3.12
Analysis 3.12
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 3.13
Analysis 3.13
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 3.14
Analysis 3.14
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 14 Response/remission 6‐24 months after treatment discontinuation.
Analysis 3.15
Analysis 3.15
Comparison 3 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy+Placebo, Outcome 15 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 4.1
Analysis 4.1
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 4.2
Analysis 4.2
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 4.3
Analysis 4.3
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 4.4
Analysis 4.4
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 4.5
Analysis 4.5
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 4.6
Analysis 4.6
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 4.7
Analysis 4.7
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 4.8
Analysis 4.8
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social malfunctioning at 2‐4 months.
Analysis 4.9
Analysis 4.9
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 4.10
Analysis 4.10
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 4.11
Analysis 4.11
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 4.12
Analysis 4.12
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 4.13
Analysis 4.13
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 4.14
Analysis 4.14
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6‐24 months after treatment discontinuation.
Analysis 4.15
Analysis 4.15
Comparison 4 PD+/‐AGORAPHOBIA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 5.1
Analysis 5.1
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 5.2
Analysis 5.2
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 5.3
Analysis 5.3
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 5.4
Analysis 5.4
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 5.5
Analysis 5.5
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 5.6
Analysis 5.6
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 5.7
Analysis 5.7
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 5.8
Analysis 5.8
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 5.9
Analysis 5.9
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 5.10
Analysis 5.10
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 5.11
Analysis 5.11
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 5.12
Analysis 5.12
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 5.13
Analysis 5.13
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 5.16
Analysis 5.16
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 5.17
Analysis 5.17
Comparison 5 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 6.1
Analysis 6.1
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 6.2
Analysis 6.2
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 6.3
Analysis 6.3
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 6.4
Analysis 6.4
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 6.5
Analysis 6.5
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 6.6
Analysis 6.6
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 6.7
Analysis 6.7
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 6.8
Analysis 6.8
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social malfunctioning at 2‐4 months.
Analysis 6.9
Analysis 6.9
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 6.10
Analysis 6.10
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 6.11
Analysis 6.11
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 6.12
Analysis 6.12
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 6.13
Analysis 6.13
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 6.18
Analysis 6.18
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 18 Response 6‐24 months after treatment discontinuation.
Analysis 6.19
Analysis 6.19
Comparison 6 SUBGROUP2: TCA: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 19 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 7.1
Analysis 7.1
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 7.2
Analysis 7.2
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 7.3
Analysis 7.3
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 7.4
Analysis 7.4
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 7.5
Analysis 7.5
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 7.6
Analysis 7.6
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 7.7
Analysis 7.7
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 7.8
Analysis 7.8
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 7.9
Analysis 7.9
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 7.10
Analysis 7.10
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 7.11
Analysis 7.11
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 7.12
Analysis 7.12
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 7.14
Analysis 7.14
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 14 Response/remission immediately after treatment discontinuation.
Analysis 7.15
Analysis 7.15
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 15 Global/Avoidance/Panic immediately after treatment discontinuation.
Analysis 7.16
Analysis 7.16
Comparison 7 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 8.1
Analysis 8.1
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 8.2
Analysis 8.2
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 8.3
Analysis 8.3
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 8.4
Analysis 8.4
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 8.5
Analysis 8.5
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 8.6
Analysis 8.6
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 8.7
Analysis 8.7
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 8.8
Analysis 8.8
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social malfunctioning at 2‐4 months.
Analysis 8.9
Analysis 8.9
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 8.10
Analysis 8.10
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 8.13
Analysis 8.13
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 8.18
Analysis 8.18
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 18 Response 6‐24 months after treatment discontinuation.
Analysis 8.19
Analysis 8.19
Comparison 8 SUBGROUP2: SSRI: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 19 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 9.1
Analysis 9.1
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 9.2
Analysis 9.2
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 9.3
Analysis 9.3
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 9.4
Analysis 9.4
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 9.5
Analysis 9.5
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 9.6
Analysis 9.6
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 9.7
Analysis 9.7
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 9.8
Analysis 9.8
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 9.9
Analysis 9.9
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 9.10
Analysis 9.10
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 9.11
Analysis 9.11
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 9.12
Analysis 9.12
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 9.13
Analysis 9.13
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 9.16
Analysis 9.16
Comparison 9 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 10.1
Analysis 10.1
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 10.2
Analysis 10.2
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 10.3
Analysis 10.3
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 10.4
Analysis 10.4
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 10.5
Analysis 10.5
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 10.6
Analysis 10.6
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 10.7
Analysis 10.7
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 10.8
Analysis 10.8
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social malfunctioning at 2‐4 months.
Analysis 10.9
Analysis 10.9
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 10.10
Analysis 10.10
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 10.11
Analysis 10.11
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 10.12
Analysis 10.12
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 10.13
Analysis 10.13
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 10.18
Analysis 10.18
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 18 Response 6‐24 months after treatment discontinuation.
Analysis 10.19
Analysis 10.19
Comparison 10 SUBGROUP3: 100%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 19 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 11.1
Analysis 11.1
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 11.2
Analysis 11.2
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 11.3
Analysis 11.3
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 11.9
Analysis 11.9
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 11.10
Analysis 11.10
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 11.11
Analysis 11.11
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 11.12
Analysis 11.12
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 11.13
Analysis 11.13
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 11.18
Analysis 11.18
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 18 Response 6‐24 months after treatment discontinuation.
Analysis 11.19
Analysis 11.19
Comparison 11 SUBGROUP3: 0%agoraphobia: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 19 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 12.1
Analysis 12.1
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 12.2
Analysis 12.2
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 12.3
Analysis 12.3
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 12.4
Analysis 12.4
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 12.5
Analysis 12.5
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 12.6
Analysis 12.6
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 12.7
Analysis 12.7
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 12.8
Analysis 12.8
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 12.9
Analysis 12.9
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 12.10
Analysis 12.10
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 12.11
Analysis 12.11
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 12.12
Analysis 12.12
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 12.13
Analysis 12.13
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 12.16
Analysis 12.16
Comparison 12 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 13.1
Analysis 13.1
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 13.2
Analysis 13.2
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 13.3
Analysis 13.3
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 13.4
Analysis 13.4
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 13.5
Analysis 13.5
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 13.6
Analysis 13.6
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 13.7
Analysis 13.7
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 13.8
Analysis 13.8
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2‐4 months.
Analysis 13.9
Analysis 13.9
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 13.10
Analysis 13.10
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 13.11
Analysis 13.11
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 13.12
Analysis 13.12
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 13.13
Analysis 13.13
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 13.14
Analysis 13.14
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6 months after treatment discontinuation.
Analysis 13.15
Analysis 13.15
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6 months after treatment discontinuation.
Analysis 13.16
Analysis 13.16
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 16 Response/remission 18‐24 months after treatment discontinuation.
Analysis 13.17
Analysis 13.17
Comparison 13 SUBGROUP4: without comorbidity: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 17 Global/Avoidance/Panic 18‐24 months after treatment discontinuation.
Analysis 14.1
Analysis 14.1
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 14.2
Analysis 14.2
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 14.3
Analysis 14.3
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 14.4
Analysis 14.4
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 14.5
Analysis 14.5
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 14.6
Analysis 14.6
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 14.7
Analysis 14.7
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 14.8
Analysis 14.8
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 14.9
Analysis 14.9
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 14.10
Analysis 14.10
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 14.11
Analysis 14.11
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 14.12
Analysis 14.12
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 14.13
Analysis 14.13
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 14.16
Analysis 14.16
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 14.17
Analysis 14.17
Comparison 14 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 15.1
Analysis 15.1
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 15.2
Analysis 15.2
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 15.3
Analysis 15.3
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 15.4
Analysis 15.4
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 15.5
Analysis 15.5
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 15.6
Analysis 15.6
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 15.7
Analysis 15.7
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 15.8
Analysis 15.8
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2‐4 months.
Analysis 15.9
Analysis 15.9
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 15.10
Analysis 15.10
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 15.11
Analysis 15.11
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 15.12
Analysis 15.12
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 15.13
Analysis 15.13
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 15.14
Analysis 15.14
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6‐24 months after treatment discontinuation.
Analysis 15.15
Analysis 15.15
Comparison 15 SENSITIVITY1: blinded rater: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 16.1
Analysis 16.1
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 16.2
Analysis 16.2
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 16.3
Analysis 16.3
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 16.4
Analysis 16.4
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 16.5
Analysis 16.5
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 16.6
Analysis 16.6
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 16.7
Analysis 16.7
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 16.8
Analysis 16.8
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 16.9
Analysis 16.9
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 16.10
Analysis 16.10
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 16.11
Analysis 16.11
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 16.12
Analysis 16.12
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 16.13
Analysis 16.13
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 16.16
Analysis 16.16
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 16.17
Analysis 16.17
Comparison 16 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 17.1
Analysis 17.1
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 17.2
Analysis 17.2
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 17.3
Analysis 17.3
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 17.4
Analysis 17.4
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 17.5
Analysis 17.5
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 17.6
Analysis 17.6
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 17.7
Analysis 17.7
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 17.8
Analysis 17.8
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2‐4 months.
Analysis 17.9
Analysis 17.9
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 17.10
Analysis 17.10
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 17.11
Analysis 17.11
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 17.12
Analysis 17.12
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 17.13
Analysis 17.13
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 17.14
Analysis 17.14
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6‐24 months after treatment discontinuation.
Analysis 17.15
Analysis 17.15
Comparison 17 SENSITIVITY2: demonstrated effectiveness: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 18.1
Analysis 18.1
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 18.2
Analysis 18.2
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 18.3
Analysis 18.3
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 18.4
Analysis 18.4
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 18.5
Analysis 18.5
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 18.6
Analysis 18.6
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 18.7
Analysis 18.7
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 18.8
Analysis 18.8
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 18.9
Analysis 18.9
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 18.10
Analysis 18.10
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 18.11
Analysis 18.11
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 18.12
Analysis 18.12
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 18.13
Analysis 18.13
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 18.16
Analysis 18.16
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 18.17
Analysis 18.17
Comparison 18 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 19.1
Analysis 19.1
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 19.2
Analysis 19.2
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 19.3
Analysis 19.3
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 19.4
Analysis 19.4
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 19.5
Analysis 19.5
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 19.6
Analysis 19.6
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 19.7
Analysis 19.7
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 19.8
Analysis 19.8
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2‐4 months.
Analysis 19.9
Analysis 19.9
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 19.10
Analysis 19.10
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 19.11
Analysis 19.11
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 19.12
Analysis 19.12
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 19.13
Analysis 19.13
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 19.14
Analysis 19.14
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6‐24 months after treatment discontinuation.
Analysis 19.15
Analysis 19.15
Comparison 19 SENSITIVITY3: operationalised criteria: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 20.1
Analysis 20.1
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 20.2
Analysis 20.2
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 20.3
Analysis 20.3
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 20.4
Analysis 20.4
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 20.5
Analysis 20.5
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 20.6
Analysis 20.6
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 20.7
Analysis 20.7
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 20.8
Analysis 20.8
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 20.9
Analysis 20.9
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 20.10
Analysis 20.10
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 20.16
Analysis 20.16
Comparison 20 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 21.1
Analysis 21.1
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 21.2
Analysis 21.2
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 21.3
Analysis 21.3
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 21.4
Analysis 21.4
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 21.5
Analysis 21.5
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 21.6
Analysis 21.6
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 21.7
Analysis 21.7
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 21.8
Analysis 21.8
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 8 Social functioning at 2‐4 months.
Analysis 21.9
Analysis 21.9
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 21.10
Analysis 21.10
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 21.14
Analysis 21.14
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6‐24 months after treatment discontinuation.
Analysis 21.15
Analysis 21.15
Comparison 21 SENSITIVITY5: without benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 22.1
Analysis 22.1
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 1 Response at 2‐4 months.
Analysis 22.2
Analysis 22.2
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 2 Remission at 2‐4 months.
Analysis 22.3
Analysis 22.3
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 3 Global severity at 2‐4 months.
Analysis 22.4
Analysis 22.4
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 22.5
Analysis 22.5
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 22.6
Analysis 22.6
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 6 General anxiety at 2‐4 months.
Analysis 22.7
Analysis 22.7
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 7 Depression at 2‐4 months.
Analysis 22.8
Analysis 22.8
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 8 Social functioning at 2‐4 months.
Analysis 22.9
Analysis 22.9
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 22.10
Analysis 22.10
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 22.11
Analysis 22.11
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 11 Response/remission on continued treatment.
Analysis 22.12
Analysis 22.12
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 22.13
Analysis 22.13
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 22.14
Analysis 22.14
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 14 Response/remission immediately after treatment discontinuation.
Analysis 22.15
Analysis 22.15
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 15 Global/Avoidance/Panic immediately after treatment discontinuation.
Analysis 22.16
Analysis 22.16
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 16 Response/remission 6‐24 months after treatment discontinuation.
Analysis 22.17
Analysis 22.17
Comparison 22 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Antidepressant alone, Outcome 17 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
Analysis 23.1
Analysis 23.1
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 1 Response at 2‐4 months.
Analysis 23.2
Analysis 23.2
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 2 Remission at 2‐4 months.
Analysis 23.3
Analysis 23.3
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 3 Global severity at 2‐4 months.
Analysis 23.4
Analysis 23.4
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 4 Frequency of panic attacks at 2‐4 months.
Analysis 23.5
Analysis 23.5
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 5 Phobic avoidance at 2‐4 months.
Analysis 23.6
Analysis 23.6
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 6 General anxiety at 2‐4 months.
Analysis 23.7
Analysis 23.7
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 7 Depression at 2‐4 months.
Analysis 23.9
Analysis 23.9
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 9 Dropouts for any reason within 2‐4 months.
Analysis 23.10
Analysis 23.10
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 10 Dropouts due to side effects within 2‐4 months.
Analysis 23.11
Analysis 23.11
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 11 Response/remission on continued treatment.
Analysis 23.12
Analysis 23.12
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 12 Global/Avoidance/Panic on continued treatment.
Analysis 23.13
Analysis 23.13
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 13 Dropouts for any reason on continued treatment.
Analysis 23.14
Analysis 23.14
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 14 Response/remission 6‐24 months after treatment discontinuation.
Analysis 23.15
Analysis 23.15
Comparison 23 SENSITIVITY5: allowed benzo: Psychotherapy+Antidepressant vs Psychotherapy alone or +Placebo, Outcome 15 Global/Avoidance/Panic 6‐24 months after treatment discontinuation.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD004364

References

References to studies included in this review

    1. Azhar MZ. Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan‐‐implications for management by family doctors. Medical Journal of Malaysia 2000;55:402‐8. - PubMed
    1. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive‐behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283:2529‐36. - PubMed
    2. Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S, Barlow DH, et al. The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. Depression and Anxiety 2003;17:88‐93. - PubMed
    3. Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM, Hofmann SG, et al. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Comprehensive Psychiatry 1998;39(6):323‐32. - PubMed
    4. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, et al. Pretreatment attrition in a comparative treatment outcome study on panic disorder. American Journal of Psychiatry 1998;155(1):43‐7. - PubMed
    5. Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D, Patterson M, et al. Effects of panic disorder treatments on personality disorder characteristics. Depression and Anxiety 1998;8(1):14‐20. - PubMed
    6. Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK, Woods SW. Therapists, therapist variables, and cognitive‐behavioral therapy outcome in a multicenter trial for panic disorder. Journal of Consulting and Clinical Psychology 2001;69:747‐55. - PubMed
    1. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive‐behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283:2529‐36. - PubMed
    2. Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S, Barlow DH, et al. The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. Depression and Anxiety 2003;17:88‐93. - PubMed
    3. Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM, Hofmann SG, et al. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Comprrehensive Psychiatry 1998;39(6):323‐32. - PubMed
    4. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, et al. Pretreatment attrition in a comparative treatment outcome study on panic disorder. American Journal of Psychiatry 1998;155(1):43‐7. - PubMed
    5. Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D, Patterson M, et al. Effects of panic disorder treatments on personality disorder characteristics. Depression and Anxiety 1998;8(1):14‐20. - PubMed
    6. Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK, Woods SW. Therapists, therapist variables, and cognitive‐behavioral therapy outcome in a multicenter trial for panic disorder. Journal of Consulting and Clinical Psychology 2001;69:747‐55. - PubMed
    1. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive‐behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000;283:2529‐36. - PubMed
    2. Gorman JM, Martinez JM, Goetz R, Huppert JD, Ray S, Barlow DH, et al. The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. Depression and Anxiety 2003;17:88‐93. - PubMed
    3. Grilo CM, Money R, Barlow DH, Goddard AW, Gorman JM, Hofmann SG, et al. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Comprehensive Psychiatry 1998;39(6):323‐32. - PubMed
    4. Hofmann SG, Barlow DH, Papp LA, Detweiler MF, Ray SE, Shear MK, et al. Pretreatment attrition in a comparative treatment outcome study on panic disorder. American Journal of Psychiatry 1998;155(1):43‐7. - PubMed
    5. Hofmann SG, Shear MK, Barlow DH, Gorman JM, Hershberger D, Patterson M, et al. Effects of panic disorder treatments on personality disorder characteristics. Depression and Anxiety 1998;8(1):14‐20. - PubMed
    6. Huppert JD, Bufka LF, Barlow DH, Gorman JM, Shear MK, Woods SW. Therapists, therapist variables, and cognitive‐behavioral therapy outcome in a multicenter trial for panic disorder. Journal of Consulting and Clinical Psychology 2001;69:747‐55. - PubMed
    1. Berger P, Sachs G, Amering M, Holzinger A, Bankier B, Katschnig H. Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. Journal of Affective Disorders 2004;80:75‐8. - PubMed
    2. Berger P, Sachs G, Amering M, Holzinger A, Maierhofer D, Bankier B, et al. Predictors of treatment‐response in panic disorder. 151st Annual Meeting of the American Psychiatric Association. 1998.
    3. Katschnig H, Berger P, Sachs G, Amering M, Holzinger A, Maierhofer D, et al. Drugs and psychotherapy in panic disorder: methodological issues. 151st Annual Meeting of the American Psychiatric Association. 1998.

References to studies excluded from this review

    1. Agras, WS, Telch, MJ, Taylor, CB, Roth, WT, Brouillard, M. Imipramine and exposure therapy in agoraphobia: untangling the actions and interactions. Telch and Lucas (1984).
    1. Ba G, Vigano C. Integrated therapy of panic disorder: a controlled study. 152nd Annual Meeting of the American Psychiatric Association. Washington DC, USA, 1999.
    2. Ba G, Vigano C. Integrated therapy of panic disorders: a controlled study. Unpublished manuscript.
    3. Vigano C, Bielli A, Carozzi A, Divino T, Pagliarulo E, Ba G. Panic disorder: A two‐year follow‐up of an integrated treatment approach. [Il disturbo di panico: follow up a due anni di un modello di trattamento integrato]. Italian Journal of Psychopathology in press.
    1. Chambless DL, Foa EB, Groves GA, Goldstein AJ. Exposure and communications training in the treatment of agoraphobia. Behavior Research and Therapy 1982;20:219‐31. - PubMed
    2. Chambless DL, Foa EB, Groves GA, Goldstein AJ. Flooding with Brevital in the treatment of agoraphobia: countereffective?. Behavior Research and Therapy 1979;17(3):243‐51. - PubMed
    1. Cox DJ, Ballanger JC, Laraia M, Hobbs WR, Peterson GA, Hucek A. Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. Journal of Behavior Therapy and Experimental Psychiatry 1988;19(2):119‐26. - PubMed
    1. Lipsedge, MS, Hajioff, J, Huggins, P, Napier, L, Pearce, J, Pike, et al. The management of severe agoraphobia: a comparison of ipronizaid and systematic desensitization. Psychopharmacologia 1973;32(1):67‐80. - PubMed

Additional references

    1. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. American Journal of Psychiatry 1998;155 Supplement:1‐34. - PubMed
    1. Brown, TA, Barlow, DH. Long‐term outcome in cognitive‐behavioral treatment of panic disorder: clinical predictors and alternative strategies for assessment. Journal of Consulting and Clinical Psychology 1995;63:754‐65. - PubMed
    1. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683‐91. - PubMed
    1. Burns, LE, Thorpe, CL, Cavallaro, LA. Agoraphobia 8 years after behavioral treatment: a follow‐up study with interview, self‐report, and behavioral data. Behavior Therapy 1986;17:580‐91.
    1. Carlbring, P, Gustafsson, H, Ekselius, L, Andersson, G. 12‐month prevalence of panic disorder with or without agoraphobia in the Swedish general population. Social Psychiatry and Psychiatric Epidemiology 2002;37:207‐11. - PubMed

MeSH terms

Substances